- A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
- Biomarker Development for Muscular Dystrophies
- Children’s Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy
- Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
- DM-IMT – Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1
- DM1 Heart Registry – DM1 Respiratory Registry
- DMCRN-02-001: Assessing Pediatric Endpoints in DM1
- Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1
- Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1
- Effects of a 12-week Strength Training Program in Women With Myotonic Dystrophy Type 1
- Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1
- Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
- Efficacy and Safety of DHEA for Myotonic Dystrophy
- Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
- European Home Mechanical Ventilation Registry
- Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert’s Disease)
- Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
- Extracellular RNA Biomarkers of Myotonic Dystrophy
- Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years
- Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1
- Multicenter Observational Study of Myotonic Dystrophy Type 1
- Myotonic Dystrophy – Vascular and Cognition
- Myotonic Dystrophy Type 1 Aerobic Exercise Study
- Myotonic Dystrophy Type 1 and Resistance Exercise
- Observational Prolonged Trial in Myotonic Dystrophy Type 1
- Open Label Study in Adolescents and Children With Myotonic Disorders
- Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients
- PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study)
- Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1
- Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients
- Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1
- Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
- Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1
- Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ?
- Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
- Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1
- Venous Thromboembolism in DM1
- Venous Thromboembolism in Myotonic Dystrophy Type 1
- Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy
Clinical Trials
- Brostallicin Clinical Trial for Myxoid Liposarcoma
- Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall (LIPO-MYX Trial)
- Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
- International Prospective Registry on Local Treatment Approaches in MLS
- Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
- ‘A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy’
- “A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA”
- “Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy”
- A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy
- A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy
- A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy
- A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
- A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
- A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness
- A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
- A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy
- A Study to Describe Diagnosis and Treatment Patterns in Narcolepsy Participants in Real Life Practice in Spain
- A Study to Evaluate Safety, and Efficacy of SUVN-G3031 in Patients With Narcolepsy With and Without Cataplexy
- A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients With Narcolepsy
- A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy
- An Interventional Safety Switch Study (IS3) of XYWAV in Narcolepsy
- An Open Label Study of FT218 in Subjects With Narcolepsy
- An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
- Anesthetic Management of Patients With Chronic Sleep Disorders
- Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder
- Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness
- Awareness and Self-Compassion Enhancing Narcolepsy Treatment
- Body Weight Regulation in Patients With Narcolepsy
- Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
- Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia
- Child and Adolescent Registry for Participants With Narcolepsy
- Clarithromycin for the Treatment of Hypersomnia
- Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)
- Development and Validation of Pediatric Narcolepsy Patient Reported Outcomes Scale
- Effect of Intranasal Administration of Orexine A on IL-6-System, Sleep-Wake-Regulation and Neurocognition
- Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy
- Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period
- Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy
- Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy
- Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration
- Evaluation of Academic and Professional Trajectories of Narcoleptic Patients
- Evaluation of Social Cognition in Patient With Type 1 or Type 2 Narcolepsy Versus Patients With Idiopathic Hypersomnia
- Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
- Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy
- Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy
- Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Behavior Disorder
- Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness
- Feasibility Study of At-Home EEG Monitoring for Hypersomnia
- Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Controlled Release) in the Treatment of Narcolepsy
- Investigation of Clinical Feature and Brain Function in Narcoleptic Patients
- Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)
- Mainz Register of Patients With Sleep Disorders
- Metabolism Characteristics in the Children With Narcolepsy
- Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies
- Microglial Activation in Narcolepsy Type 1: Positron Emission Tomography (PET) Study in [18F] DPA-714
- Narcolepsy – New Potential Treatment
- Narcolepsy Nightmare Study
- Narcolepsy Protect Against Alzheimer’s Disease?
- Neurophysiologic Correlates of Hypersomnia
- Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription
- Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
- Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)
- Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR)
- Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)
- Provigil (Modafinil) Study by Taiwan Biotech Co.
- PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
- Psychosocial Adjunctive Treatment for Hypersomnia (PATH)
- Risk of Narcolepsy Associated With Administration of H1N1 Vaccine
- Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients
- Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients
- Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy
- Sleep Disorders of Patients With Diseases of the Nervous System
- Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence
- Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy
- Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
- Study of the Academic and Professional Course of Narcoleptic Patients (NARCOSCOL-NARCOVITAE)
- Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
- Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)
- Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
- Swiss Primary Hypersomnolence and Narcolepsy Cohort Study
- TElemedicine for NARcolepsy
- The Effect of Caffeine on the Narcoleptic Patients
- The Nuvigil and Provigil Pregnancy Registry
- The Role of the Circadian System in Neurological Sleep-wake Disorders
- The Value of Combined Detection of Orexin-A, HLA Gene, PSG and MSLT in the Evaluation of Patients With Narcolepsy
- This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.
- Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy
- Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy
- WAKIX® (Pitolisant) Pregnancy Registry
- Xyrem and Brain Dopamine in Narcolepsy
- 177Lu-EB-LM3 in Nasopharyngeal Carcinoma
- 18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
- 18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma – a Feasibility and Planning Study
- 3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma
- 3DV+TPS Software Outlines the Radiotherapy of Nasopharyngeal Carcinoma
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.
- A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma
- A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
- A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
- A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy
- A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma
- A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
- A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma Patients
- A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
- A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation
- A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC
- A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
- A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma
- A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
- A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
- A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma Patients
- A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
- A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
- A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy
- A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
- A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma
- A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer
- A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors
- A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer
- A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer
- A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
- A Study of Nasopharyngeal Carcinoma From Guangdong
- A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
- A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma
- A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.
- A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects
- A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma
- A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
- A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma
- A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma
- A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC
- Acupuncture for Prevention of Radiation-Induced Xerostomia
- Acute Radiation Oral Mucositis in Nasopharyngeal Carcinoma(NPC) Patients Treated With Combined Radio-Chemotherapy
- Adding Neoadjuvant and Adjuvant PD-1 Inhibitor to Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy in the Treatment of High-risk Nasopharyngeal Carcinoma
- Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
- Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma
- Administration of Epstein Barr Virus – Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer
- An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
- An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
- Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
- Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC With Induced Chemotherapy Resistance
- Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
- Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
- Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasopharyngeal Carcinoma After Radiotherapy: a Multicenter Randomized Controlled Clinical Study
- Applying PET/MR in Oncology – a Prospective Project
- Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients
- Assessment of New Radiation Oncology Technologies and Treatments
- Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI
- Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis
- Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
- Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
- BGT007 Cell Treatment of Nasopharyngeal Carcinoma
- Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC)
- Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
- Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer
- Bupropion Hydrochloride or Patient’s Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
- By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC
- Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma
- Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
- Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma
- Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma
- Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
- Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
- Camrelizumab Combined With Induction Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
- Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
- Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment
- Carbon-Ion Radiotherapy Plus Camrelizumab With or Without Apatinib for Locally Recurrent Nasopharyngeal Carcinoma
- Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes
- CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC
- Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)
- Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin
- Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
- Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma
- Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma
- Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma
- Clincal Study of Reduced Target Radiotherapy in Nasopharyngeal Carcinoma
- Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma
- Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment
- Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
- Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV) Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV) Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
- CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy
- Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC
- Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma
- Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients
- Combining PET/CT and EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced NPC
- Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma
- Comparison of Oxycodone to Control Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy
- Comparison of Transdermal Fentanyl and Morphine for Oral Mucositis Pain in Nasopharyngeal Cancer Patients
- Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma
- Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
- Concurrent and Adjuvant PD-1 Blockade Combined With Induction Chemotherapy Plus Radiotherapy in Nasopharyngeal Carcinoma
- Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
- Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma
- Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma
- Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma
- Concurrent Chemoradiotherapy With or Without Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Phase 2, Multicentre, Randomised Controlled Trial
- Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma
- Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era
- Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy
- Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma
- Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC
- Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
- De-escalation Protocols in HPV-related Oropharyngeal Carcinoma in Chinese Populations
- De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma
- Delineation of Reducing Clinical Target Volume for Early-stage Nasopharyngeal Carcinoma Patients
- Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma
- Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma
- Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours
- Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
- Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images
- Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images
- Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
- Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients
- Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients
- Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
- Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC
- Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma
- Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
- Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy
- Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma
- Early Nutritional Intervention in NPC Patients Undergoing Concurrent Chemoradiotherapy
- EBV CAR-T Cells for Nasopharyngeal Carcinoma
- EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
- Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma
- Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC Patients
- Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis
- Effect of Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Locoregionally Advanced,Low-risk Nasopharyngeal Carcinoma
- Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases
- Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma
- Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma Patients
- Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
- Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma
- Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma
- Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
- Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma
- Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines
- Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma
- Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
- Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma
- Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
- Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma
- Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma
- Endostar for Locally Recurrent Nasopharyngeal Carcinoma
- Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma
- Environmental and Genetic Determinants of Nasopharyngeal Carcinoma (NPC)
- Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
- EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)
- Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
- EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients
- Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography
- Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in China
- Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy
- Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
- Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
- Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
- Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma
- GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma
- Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma
- Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
- Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
- GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
- GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma
- Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
- Hearing Toxicity of Nasopharyngeal Carcinoma After Chemoradiotherapy
- HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma
- Hepatic Artery Infusion Pump for NPC Liver Metastases
- Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients
- Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma
- Hypoxia Imaging -Guided Radiotherapy of Nasopharyngeal Carcinoma
- Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma
- Immune Score Based Radiomics in Nasopharyngeal Carcinoma
- Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma
- Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated Radiotherapy
- IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.
- IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma
- Individualized Carbon-Ion Radiotherapy for Patients With Locally Recurrent Nasopharyngeal Carcinoma
- Individualized Elective Neck Irradiation Based on MRI in NPC Patients
- Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
- Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma
- Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers
- Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With IMRT Of Locally Advanced NPC Clinical Study
- Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)
- Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC
- Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer
- Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
- Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
- Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma
- Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma
- Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma
- Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
- Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma
- Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
- Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma
- Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma
- Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma
- Intestinal Flora Sequencing for Nasopharyngeal Carcinoma
- KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial
- KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy
- Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy
- Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma
- LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
- LMP2-Specific IL12-secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma
- Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA
- Magnifying NBI for Occult NPC
- Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma
- Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage
- Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma
- Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
- Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.
- MK-2206 in Recurrent Nasopharyngeal Carcinoma
- Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT
- Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s)
- Molecular Mechanism of Nasopharyngeal Carcinoma
- Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
- Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
- Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study
- Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC
- Nasopharyngeal Carcinoma Post IMRT
- Nasopharyngeal Carcinoma Screening in Zhongshan City
- NBI to Detect Post-RT Mucosal Residual NPC
- Nedaplatin in Treatment for Nasopharyngeal Carcinoma
- Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC
- Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
- Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
- Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
- Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
- Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma
- Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC
- New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer
- Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma
- Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
- Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
- Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma
- Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
- Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)
- Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy
- Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment
- Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
- NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
- Olfactory Change After Chemo-radiotherapy for Nasopharyngeal Carcinoma
- Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions
- OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy
- Optimization of Cervical Nodal Clinical Tumor Volume for Early and Medium Stage Nasopharyngeal Carcinoma
- Ovarian Function of Nasopharyngeal Carcinoma Women Survivors
- P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
- Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma
- Parotid-sparing IMRT for Nasopharyngeal Cancer
- PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
- PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma
- PD-1 Combined With IMRT in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma
- PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab for Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First Line Chemotherapy
- PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
- PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma
- Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer
- Peramprizumab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma
- PET and MRI in Prognosis Prediction of NPC
- PET/MR in Locally Advanced Nasopharyngeal Carcinoma
- Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
- Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
- Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients
- Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC
- Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
- Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma
- Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma
- Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients
- Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC
- Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
- Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma
- Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA
- Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma
- Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx
- Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer
- Plasma EBV DNA Monitoring in Post-treatment NPC Patients
- Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
- Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
- Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma
- Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma
- Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-up of Nasopharyngeal Carcinoma.
- Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients
- Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined Chemotherapy
- Preliminary Analysis of Recurrent/Metastatic Nasopharyngeal Carcinoma Patients: a Phase II Study
- PRO1160 for Advance Solid and Liquid Tumors (PRO1160-001)
- Prognostic Utility of the Imaging and Biological Signatures in Nasopharyngeal Carcinoma
- Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
- Programmed Death-1 (PD-1) Antibody Combined With IMRT in Recurrent Nasopharyngeal Carcinoma Patients
- Prospective Comparisons of Clinical Trial and Real-world Outcomes in Nasopharyngeal Carcinoma
- Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis
- Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue
- Prospective Study for Prognostic Biomarkers of Nasopharyngeal Carcinoma
- Proton Versus Photon Radiotherapy for Nasopharyngeal Carcinoma
- Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Radiation-associated Carotid Artery Disease in Patients With Nasopharyngeal Carcinoma
- Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC
- Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy
- Radiotherapy Combined With Endostatin and Capecitabine for NPC
- Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma
- Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma
- Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
- Reactivating NK Cells in Treating Refractory Head and Neck Cancer
- Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis
- Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
- Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
- Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
- Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma
- Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain
- Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy
- Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli
- S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
- Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma
- Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
- SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
- SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma
- Screening for Nasopharyngeal Carcinoma in High Risk Populations
- Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
- Secretomes for Patients With Advanced Nasopharyngeal Cancer
- Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC
- Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients
- Serial Plasma EBV DNA for Nasopharyngeal Carcinoma
- SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.
- SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
- Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study
- Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
- Somatostatin Receptor Imaging in NPC, EBV Related Cancers
- SOX as Salvage Treatment in Nasopharyngeal Carcinoma
- Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
- Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
- Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma
- Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy
- Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
- Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma
- Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma
- Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
- Study of DC-CIK to Treat NPC
- Study of DC-CTL Combined With CIK for Advanced Solid Tumor
- Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)
- Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
- Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
- Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
- Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)
- Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
- Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Primary Locally Resectable Nasopharyngeal Carcinoma
- Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma
- Swallowing Exercises for Nasopharyngeal Cancer After Radiation Therapy
- Swallowing Pattern of Patients With Nasopharyngeal Cancer Before and After Radiation Therapy: Longitudinal Study and Correction With Saliva Amount
- Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
- Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRT
- Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC
- Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis
- Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
- The Association of hsCRP and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal Carcinoma
- The Diagnosis of NPC Using the Probe-based Confocal Laser Endomicroscopy
- The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma
- The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients
- The Influence of Anxiety and Depression on Survival in Nasopharyngeal Carcinoma Patients
- The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma
- The Prognostic Value of Human Papilloma Virus in Nasopharyngeal Carcinoma
- The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT
- The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
- The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma
- The Value of Post-radiation Detectable Plasma EBV DNA in High-risk Nasopharyngeal Carcinoma Patients
- The Value of Single-cycle TPF Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
- Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma
- Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma
- To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
- To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
- To Evaluate the Feasiblity of Recommendations About Selective Irradiation to Level Ib in the International Guideline.
- To Evaluate Transoral Flexible Endoscope With Narrow Band Imaging in Nasopharyngeal Cancer
- To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma
- To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal Carcinoma
- TOMO Versus IMRT in Nasopharyngeal Carcinoma Patients
- Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
- Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
- Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC
- Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
- Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
- Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
- Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
- Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma
- TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma
- TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma
- TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- Trail Evaluating Carbon Ion Radiotherapy (3 GyE Per Fraction) for Locally Recurrent Nasopharyngeal Carcinoma
- Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma
- Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma
- Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
- Treatment Individualisation by EBV Stratification in Nasopharyngeal Carcinoma: a Prospective Observational Study
- Treatment of Bevacizumab Followed by Steroid in RN
- Treatment of Cerebral Radiation Necrosis With GM1, a Prospective Study
- Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients
- Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
- Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma
- Trial of E10A in Head and Neck Cancer
- Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma
- Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
- Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC
- Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma
- Ultrasensitive Positron Emission Tomography in NPC Patients
- Umbrella Biomarker-Guided Therapy in NPC
- Using Massage of Maxillofacial and Oral Cavity to Prevent Radioactive Oral Mucositis
- Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma
- Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements
- Vestibular Function After Chemoradiotherapy for Nasopharyngeal Carcinoma
- Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma
- Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer
- Weekly Plasma EBV DNA for Non-metastatic Nasopharyngeal Carcinoma
- Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients
- Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma
- A Biologic Validation of Biomarkers of Progressive NEC & Sepsis
- a Clinical Risk Score to Predict Bloody Stool in Neonates
- A Cohort Study of the Intestinal Microbiota of Premature Infants
- A Genome-Wide Association Study for Neonatal Diseases
- A Multi-strain Synbiotic Versus a Multi-strain Probiotic in Premature Infants
- A Panel of Biomarkers in Diagnosing Late-onset Neonatal Sepsis and Necrotizing Enterocolitis in Sibu Hospital
- A Randomised Controlled Trial to Compare Primary Anastomosis Versus Enterostomy in the Surgical Treatment of Necrotising Enterocolitis
- Administration of Arginine Supplementation in Preterm Infants
- Alteration of Stool Microbiota in Preterm Infants With Anemia
- Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants
- Assessment of Score System of Surgery in Necrotizing Enterocolitis(NEC) Patients
- Association of Red Blood Cell Transfusion, Anemia, and Necrotizing Enterocolitis
- Bovine Colostrum as a Fortifier Added to Human Milk for Preterm Infants
- Bovine Colostrum for Preterm Newborns
- Bovine Lactoferrin and Neonatal Survival in Low Birth Weight Babies.
- Bowel Preparation in Elective Pediatric Colorectal Surgery
- CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis
- Characterization of Intestinal Microbiota Stability in Preterm Born Neonates
- Clostridium and Neonatal Necrotizing Enterocolitis Pathophysiology : Clinical and Molecular Approaches
- Cohort of Premature Newborns for Charaterization of the Digestive Microbiota in Ulcerative Necrotizing Enterocolitis in Premature Infants
- Collaborative Research Group for Necrotizing Enterocolitis
- Comparative Effectiveness Trial for Diagnosis of Necrotizing Enterocolitis
- Comparison of Two Surgical Treatments for Necrotizing Enterocolitis in Human Infants
- Defining Normal Citrulline Levels as a Diagnostic Tool for Screening of Gastrointestinal Disease in Premature Infants
- Defining the Intestinal Microbiota in Premature Neonates
- Early Predictors of Necrotizing Enterocolitis in Neonates
- Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy
- Early Routine vs. Selective Human Milk Fortification in Extremely Preterm Infants
- Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies
- Effect of Autologous Cord Blood Mononuclear Cells for Digestive System in Preterm Neonates
- Effect of Melatonin on Feeding Intolerance and Incidence of Necrotizing Enterocolitis in Preterm Infants
- Effect of Saccharomyces Boulardii on Necrotizing Enterocolitis in Very Low Birth Weight Infants
- Effect of Vitamin A in the Treatment of Neonatal Sepsis and Necrotizing Enterocolitis
- Effects of Delayed Cord Clamping in Very Low Birth Weight Infants
- Effects of Oral Probiotic Supplementation on the Clinical Status of Very-low-birth-weight Preterm Neonates.
- Efficacy Of Oral Melatonin To Prevent Necrotizing Enterocolitis
- Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates
- Enteral Granulocyte Colony Stimulating Factor and Erythropoietin Early in Life Increases Feeding Tolerance in Preterm Infants: A Randomized Controlled Trial
- Evaluation of Abdominal Tissue Oxygenation in Premature Infants Using Near Infrared Spectroscopy
- Evaluation of Feeding Intolerance in Premature Infants Using Near Infrared Spectroscopy
- Feeding Bovine Colostrum to Preterm Infants
- Genomics, Single Nucleotide Polymorphisms (SNPs), and Clinical Neonatology
- Gut Priming With Oral Bovine Colostrum for Preterm Neonates; Randomized Control Trial
- Heat Killed Probiotics in the Prevention of Necrotizing Enterocolitis
- Human Milk Fortification in Extremely Preterm Infants
- Human Milk-derived Fortification in Preterm Infants
- IBP-9414 for the Prevention of Necrotizing Enterocolitis
- IBP-9414 for the Prevention of Necrotizing Enterocolitis – The Connection Study
- Imaging Modalities in Diagnosing Necrotizing Enterocolitis in Preterm Infants.
- Incidence, Risk Factors, Severity and Prognosis of Necrotizing Enterocolitis in Turkey
- Infant Formula Feeding and Necrotizing Enterocolitis in Newborns
- Infloran® for Prevention of Necrotizing Enterocolitis
- Intestinal Failure in Necrotising Enterocolitis
- Intragastric and Peritoneal Microdialysis in Infants With Necrotizing Enterocolitis (NEC)
- IRT in Infants With Intestinal Perforation
- Lactobacillus Reuteri for Prevention of Necrotizing Enterocolitis in Very Low-birth Weight Infants
- Lactoferrin Prophylaxis in VLBW and Regulator T-cells
- Lactulose Supplementation in Premature Infants
- Long-term Consequences of Necrotizing Enterocolitis in the Newborn Period
- Markers of Platelet Activation foR Identification of Late Onset Sepsis in Preterm Infants
- Metronidazole Pharmacokinetics (PK) in Premature Infants
- Monitoring Necrotizing Enterocolitis in Premature Infants
- Monitoring of Systemic or Organ Perfusion for Preterm Infants
- NEC Thermography Infrared Imaging Study
- Necrotizing Enterocolitis (Nec) and B. Lactis in Premature Babies
- Necrotizing Enterocolitis (NEC) Surgical Database
- Necrotizing Enterocolitis in Fetuses With Intrauterine Growth Restriction
- NETs: Protection or Harm in Neonatal Inflammation or Infection
- Neutrophil Extracellular Trap Formation in Newborn Infants at Risk for Inflammatory Syndromes
- NIRS and Doppler to Predict NEC in Risk Neonates
- Optimising Newborn Nutrition During Therapeutic Hypothermia.
- Pentoxifylline in the Treatment of NEC in Premature Neonates
- Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections
- Placental Transfusion Project for Preterm Infants
- Prebiotics in the Prevention of Necrotizing Enterocolitis
- Prediction of NEC With Urinary iFABP
- Predictors of Neonatal Necrotizing Enterocolitis
- Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants
- Probiotic Administartion to Mothers of Preterm Infants to Prevent Necrotizing Enterocolitis and Sepsis
- Probiotic Supplementation in Extremely Preterm Infants in Scandinavia
- Probiotics in the Management of Necrotizing Enterocolitis in HIV-exposed Premature Infants
- Probiotics to Prevent NEC – a Historical Control Study
- Probiotics/TPN in the NICU
- Prognostic Contribution of Abdominal Ultrasound in Necrotizing Enterocolitis in Preterm Infants Less Than 33SA.
- Prophylactic Probiotics to Extremely Low Birth Weight Prematures
- RBC Irradiation, Anemia and Gut Injury
- Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis
- Role of Probiotic Use in Outcomes of Premature Birth
- Role of Probiotics for Prevention of NEC in Preterm VLBW Infants
- Simulated Amniotic Fluid In Preventing Feeding Intolerance and Necrotizing Enterocolitis VLBW Neonates
- Simulated Amniotic Fluid Solution in Neonates Recovering From GIT Surgeries
- SMA Flow Patterns in Neonatal Transfusion
- Spectral Analysis of Bowel Sounds in Preterm Babies of Less Than 32 Weeks of Amenorrhea (WA) as Predictive Factor of Enterocolitis
- Speed of Increasing Milk Feeds Trial
- Splanchnic Oxygenation After the First Enteral Feed in Preterm Infants: Prediction of Feeding Tolerance.
- Splanchnic Oxygenation Response to Feeds in Preterm Neonates: Effect of Red Blood Cell Transfusion
- Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis
- Standardised Enteral Feeding in Infants With Duct Dependant Lesions; a Randomised Control Trial.
- Study of the Relationship Between Feeding and Late Onset Sepsis and/or Necrotizing Enterocolitis in Low Birth Weight Infants
- Study to Determine if Gloving in Addition to Hand Hygiene Will Prevent Invasive Infections and Necrotizing Enterocolitis
- Temperature of Extremities and Necrotizing Enterocolitis
- The Efect of Azithromicyn on Bronchopulmonary Displasia in Extremely Preterm and Very Preterm Infant
- The Effect of β-Carotene, Vitamin D3 and Zinc on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates
- The Effects of Synbiotics on Morbidity and Mortality in Preterm Infants
- The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis
- The Efficacy of Symbiotic on Cytokines
- The Impact of Different Feeding Strategies During Packed Red Cell Transfusion on Intestinal Oxygenation
- The Impact of Docosahexaenoic Acid on the Prevention of Necrotizing Enterocolitis in Preterm Neonates
- The Intestinal Dysbacteriosis in the Pathogenesis of Necrotizing Enterocolitis
- The Relationship Between Erythrocyte Transfusion and Nutrition and Necrotizing Enterocolitis in Preterm Infants
- The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery.
- The Role of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis (NEC) in Pre-term Infants
- Therapeutic Controlled Hypothermia in the Treatment of Neonates With Severe Necrotizing Enterocolitis
- Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates
- Transfusions and Nitric Oxide Level in Preterm Infants
- Treatment of Classic Mid-trimester PPROM by Means of Continuous Amnioinfusion
- Ultrasound, Doppler ,and Calprotectin in Necrotizing Enterocolitis Diagnosis
- Use of Faecal Calprotectin to Predict Enteropathy of the Preterm Neonates
- Biomarkers in Patients With Flesh-eating Bacterial Infections
- Compare Effects of Dressing With Honey and EUSOL
- Detection and Delineation of Necrotizing Fasciitis Via a Vascular Perfusion Fluorophore
- Factors Associated With Complications of Cervical Necrotizing Fasciitis
- Genetic Susceptibility to Severe Streptococcal Infections
- Hyperglycemia in Surgical Infections
- Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial
- Klebsiella Pneumoniae Necrotizing Fasciitis: Clinical and Microbiological Features
- Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment
- Outcome and Related Factors of Necrotizing Fasciitis of the Limb
- Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
- Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study
- RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
- Severe Soft Tissue Infections: Perspectives of Patients and Significant Others
- SKin and Soft Tissue Necrotizing INfections in the Intensive Care Unit: a Prospective Multi-national Cohort Study
- Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs).
- Dose Comparison Study of Menactra® in US Children
- Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)
- Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection
- Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults
- Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia
- Investigating Meningococcal Vaccines in Adults
- Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals’ Hib-MenCY-TT Vaccine Compared to ActHIB
- Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals’ Hib-MenC
- Neisseria Meningitidis Burden of Disease Study
- Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
- Primary & Booster Immunogenicity Study of GSK Biologicals’ Hib-MenC Versus a Licensed Men-C Vaccine
- Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine
- Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals’ Hib-MenC & to Evaluate Persistence up to 5 Years.
- Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
- Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers
- Impact of Thrombocytopenia and Platelet Transfusions on Neonatal Bleeding and Inflammation
- Kinetics of Blood Platelets Transfused to Healthy Subjects
- Mathematical Modeling to Predict the Duration of Thrombocytopenia in Neonates
- Monitoring Outcome in Neonatal Thrombocytopenia
- Neurodevelopmental Outcome After Fetal Neonatal AlloImmune Thrombocytopenia
- Study on the Anti-HPA Antibodies Caused Neonatal Alloimmune Thrombocytopenia in Chinese Pregnant Women
- Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
- The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
- Towards Routine HPA-screening In Pregnancy to Prevent FNAIT
- Bilicurves: Using Information Technology to Improve the Management of Neonatal Hyperbilirubinemia
- Broad Band Emission LED Phototherapy Source Versus Narrow Band
- Clinical and Developmental Outcomes of Babies Who Became Yellow in the First Month of Life
- Comparison Between Effect of Conventional, Intensive and Light Emitting Diodes (LED) Phototherapy on Oxidative Stress Among Neonates With Unconjugated Hyperbilirubinemia
- Comparison of Double Pad Fiber Optic Device Versus Conventional Phototherapy
- Comparison of Phototherapy Using Neolight Skylife Versus Standardized Phototherapy for Hyperbilirubinemia in Newborns
- Compassionate Use of Stanate (TM) [Stannsoporfin]
- Conventional Versus LED Phototherapy and Their Effect on Lymphocytes Subsets of Full Term Neonates With Hyperbilirubinemia
- Dose-response Relationship of Phototherapy for Hyperbilirubinaemia Using Diodes: is There a “Saturation Point”
- Early Versus Delayed Cord Clamping at Term: Outcomes in Swedish Infants
- Effect of DCC on Neonatal Jaundice and Blood Gas Analysis in Infants Born to GDM Mothers
- Effects of Probiotics on Neonatal Hyperbilirubinemia
- Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency
- Fenofibrate Therapy in Pathological Unconjugated Hyperbilirubinemia in Full Term Infants
- Follow-up of Extreme Neonatal Hyperbilirubinemia in 5-10 Year Old Children: a Danish Population Based Study
- Glycerin Suppositories to Reduce Jaundice in Premature Infants
- Home Phototherapy for Term Newborns With Icterus
- Implementation of a Transcutaneous Bilirubinometer
- Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis
- Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993)
- Parental Participation on the Neonatal Ward – the neoPARTNER Study
- Reverse Phototherapy With Super Light-emitting Diode(Super-LED) for Hyperbilirubinemia in Term and Late Preterm Infants
- Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn
- Study on Newborn Babies With a Yellow Skin Color (Neonatal Jaundice Study)
- Tactile and Kinaesthetic Stimulation in Neonates With Hyperbilirubinaemia
- The Effect of Intravenous Oxytocin Infusion Using Different Diluents on Neonatal Bilirubin & Sodium Levels
- Transcutaneous Bilirubinometry and Phototherapy
- Transcutaneous Bilirubinometry in Neonates
- Use of a New Phototherapy Device (BBloo®) for the Treatment of Hyperbilirubinemia in the Newborn Infant